Skip to main content
Erschienen in: Annals of Hematology 11/2016

30.07.2016 | Letter to the Editor

Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma

verfasst von: Thomas S. Y. Chan, Pek-Lan Khong, Yok-Lam Kwong

Erschienen in: Annals of Hematology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439–3443CrossRefPubMed Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439–3443CrossRefPubMed
2.
Zurück zum Zitat Carbone A, Gloghini A, Kwong YL, Younes A (2014) Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 93(8):1263–1277CrossRefPubMedPubMedCentral Carbone A, Gloghini A, Kwong YL, Younes A (2014) Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 93(8):1263–1277CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A (2015) Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 170(4):504–514CrossRefPubMed Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, Nasta SD, Feldman T, Rago A, Walsh KM, Weber S, Goy A, Mato A (2015) Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol 170(4):504–514CrossRefPubMed
4.
Zurück zum Zitat Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Snyder E, Marinello P, Shipp MA, Armand P (2015) Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). 4: Blood, Absract 3986 Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Snyder E, Marinello P, Shipp MA, Armand P (2015) Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). 4: Blood, Absract 3986
5.
Zurück zum Zitat Ding W, Dong H, Call TG, Shanafelt TD, Parikh SA, Leis JF, Laplant BR, He R, Witzig TE, Lin Y, Chanan-Khan A, Bowen DA, Conte M, Habermann TM, Viswanatha D, Micallef I, Kay NE, Ansell S (2015) Blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including Richter transformation: an early efficacy report from a phase 2 trial (MC1485). Blood, Abstract 834 Ding W, Dong H, Call TG, Shanafelt TD, Parikh SA, Leis JF, Laplant BR, He R, Witzig TE, Lin Y, Chanan-Khan A, Bowen DA, Conte M, Habermann TM, Viswanatha D, Micallef I, Kay NE, Ansell S (2015) Blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including Richter transformation: an early efficacy report from a phase 2 trial (MC1485). Blood, Abstract 834
6.
Zurück zum Zitat Nowakowski GS, Laplant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33(3):251–257CrossRefPubMed Nowakowski GS, Laplant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 33(3):251–257CrossRefPubMed
7.
Zurück zum Zitat Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33(25):2803–2811CrossRefPubMed Gribben JG, Fowler N, Morschhauser F (2015) Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 33(25):2803–2811CrossRefPubMed
Metadaten
Titel
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma
verfasst von
Thomas S. Y. Chan
Pek-Lan Khong
Yok-Lam Kwong
Publikationsdatum
30.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2016
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2771-2

Weitere Artikel der Ausgabe 11/2016

Annals of Hematology 11/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.